p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies

4′,7-Di-O-methylnaringenin (DMNG), a naringenin derivative, activates p53 signal pathway through down-regulating MDM2

(2022) Siyu Zhang et al.   Journal of Functional Foods

Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program

(2022) Vaitheeswaran Kulothungan et al.   BMC CANCER

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death

(2022) Nayeong Koo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

(2022) Daniil R. Bazanov et al.   Pharmaceuticals

New 2-[(4-Amino-6-N-substituted-1,3,5-triazin-2-yl)methylthio]-N-(imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide Derivatives, Design, Synthesis and Anticancer Evaluation

(2022) Łukasz Tomorowicz et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX

(2022) Yali Wang et al.   MOLECULES

Computational-Model-Based Biopharmaceutics for p53 Pathway Using Modern Control Techniques for Cancer Treatment

(2022) Amina Yasin et al.   Applied Sciences-Basel

Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6,7,8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors

(2022) Ashish Ranjan Dwivedi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors

(2022) Margarida Espadinha et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and evaluation of 4-phenyl-1,2,3-triazole substituted pyrimidine derivatives as antiproliferative and tubulin polymerization inhibitors

(2022) Ashish Ranjan Dwivedi et al.   JOURNAL OF MOLECULAR STRUCTURE

Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma

(2022) Assem Barakat et al.   BIOORGANIC CHEMISTRY

Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

(2021) Adekemi Taylor et al.   Clinical Pharmacology in Drug Development

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Synthesis and therapeutic potential of imidazole containing compounds

(2021) Ankit Siwach et al.   BMC Chemistry

Design, synthesis and biological evaluation of novel 5-(4-chlorophenyl)-4-phenyl-4H-1,2,4-triazole-3-thiols as an anticancer agent

(2021) Krupa R. Patel et al.   JOURNAL OF MOLECULAR STRUCTURE

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53

(2021) Mansoor N Saleh et al.   CLINICAL CANCER RESEARCH

Design, Synthesis, and Antitumor Activity of Novel Dispiro[oxindole-cyclohexanone]-pyrrolidines

(2021) Magy Gouda et al.   CURRENT PHARMACEUTICAL DESIGN

Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness

(2021) Joana Moreira et al.   MOLECULES

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

(2021) Sophia Ceder et al.   Cell Death & Disease

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

(2021) Dongjuan Si et al.   BIOORGANIC CHEMISTRY

Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators

(2021) Gehad Lotfy et al.   BIOORGANIC CHEMISTRY

Stereoselective Synthesis of the Di-Spirooxindole Analogs Based Oxindole and Cyclohexanone Moieties as Potential Anticancer Agents

(2021) Abdullah Mohammed Al-Majid et al.   MOLECULES

Discovery of thiazole-based-chalcones and 4-hetarylthiazoles as potent anticancer agents: Synthesis, docking study and anticancer activity

(2020) Thoraya A. Farghaly et al.   BIOORGANIC CHEMISTRY

Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction

(2020) Anastasia Beloglazkina et al.   MOLECULES

Synthesis and Biological Evaluation of Novel Dispiro Compounds based on 5-Arylidenehydantoins and Isatins as Inhibitors of p53–MDM2 Protein–Protein Interaction

(2020) Anastasia Beloglazkina et al.   Chemistry of Heterocyclic Compounds

Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors

(2020) Abdel-Ghany A. El-Helby et al.   BIOORGANIC CHEMISTRY

The importance of indole and azaindole scaffold in the development of antitumor agents

(2020) Yu Han et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Ursolic Acid-Based Derivatives as Potential Anti-Cancer Agents: An Update

(2020) Vuyolwethu Khwaza et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Novel 1,2,4-triazole derivatives as apoptotic inducers targeting p53: Synthesis and antiproliferative activity

(2020) Hesham A.M. Gomaa et al.   BIOORGANIC CHEMISTRY

Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2–p53 interaction

(2019) Assem Barakat et al.   BIOORGANIC CHEMISTRY

Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents

(2019) Lemos et al.   MOLECULES

COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms

(2019) Antje Lindemann et al.   CLINICAL CANCER RESEARCH

Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway

(2019) Qing-Kun Shen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

(2019) Naoise C. Synnott et al.   BREAST CANCER RESEARCH AND TREATMENT

The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy

(2019) Yao Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of mutant Kras and p53‐driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53

(2019) Dandan Xu et al.   MOLECULAR CARCINOGENESIS

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

(2019) Isabelle Ray-Coquard et al.   Frontiers in Oncology

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

(2019) Courtney D. DiNardo et al.   BLOOD

2-Styryl-4-aminoquinazoline derivatives as potent DNA-cleavage, p53-activation and in vivo effective anticancer agents

(2019) Xin-Wei Wei et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

(2019) Douglas D. Fang et al.   Journal for ImmunoTherapy of Cancer

Towards the overcoming of anticancer drug resistance mediated by p53 mutations

(2019) Xin Cao et al.   DRUG RESISTANCE UPDATES

DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions

(2018) Jie Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity

(2018) Pedro Brandão et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Regio- and stereoselective synthesis of new spirooxindoles via 1,3-dipolar cycloaddition reaction: Anticancer and molecular docking studies

(2018) Gehad Lotfy et al.   JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY

Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1

(2018) Wei Hang et al.   ONCOGENE

Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael–aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity

(2018) Shengzheng Wang et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Synthesis and cytotoxicity of novel dispiro derivatives of 5-arylidenoxazolones, potential inhibitors of p53—MDM2 protein-protein interaction

(2018) A. А. Beloglazkina et al.   RUSSIAN CHEMICAL BULLETIN

Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201

(2018) Sébastien Jeay et al.   CANCER RESEARCH

Mutant p53 as a guardian of the cancer cell

(2018) Fiamma Mantovani et al.   CELL DEATH AND DIFFERENTIATION

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

(2018) Lukasz Skalniak et al.   Cancers

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

(2017) Angelo Aguilar et al.   JOURNAL OF MEDICINAL CHEMISTRY

Imidazoles as potential anticancer agents

(2017) Imran Ali et al.   MedChemComm

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner

(2017) Evguenia M Alexandrova et al.   Cell Death & Disease

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

(2017) Shaomeng Wang et al.   Cold Spring Harbor Perspectives in Medicine

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

(2017) Anne Perdrix et al.   Cancers

A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

(2016) S. Bauer et al.   ANNALS OF ONCOLOGY

Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review

(2016) Ramandeep Kaur et al.   Anti-Cancer Agents in Medicinal Chemistry

Tumor-Suppressor Functions of the TP53 Pathway

(2016) Brandon J. Aubrey et al.   Cold Spring Harbor Perspectives in Medicine

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy

(2016) Vladimir J. N. Bykov et al.   Frontiers in Oncology

Spirooxindoles: Promising scaffolds for anticancer agents

(2015) Bin Yu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Small-molecule MDM2-p53 inhibitors: recent advances

(2015) Bian Zhang et al.   Future Medicinal Chemistry

RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38

(2014) A Weilbacher et al.   Cell Death & Disease

Comprehensive Review in Current Developments of Imidazole-Based Medicinal Chemistry

(2013) Ling Zhang et al.   MEDICINAL RESEARCH REVIEWS

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Tied Up in Loops: Positive and Negative Autoregulation of p53

(2009) X. Lu   Cold Spring Harbor Perspectives in Biology

Cancer cells suppress p53 in adjacent fibroblasts

(2008) J Bar et al.   ONCOGENE